Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS

Zeng,Xinxin; Wang,Shengtao; Gui,Peng; Wu,Hao; Li,Zhaoxu

doi:10.3892/mmr.2019.10513

Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS

Authors:
- Xinxin Zeng
- Shengtao Wang
- Peng Gui
- Hao Wu
- Zhaoxu Li
View Affiliations

Affiliations: Department of Orthopaedics, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Emergency and Trauma Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Orthopaedics, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541002, P.R. China
Published online on: July 23, 2019 https://doi.org/10.3892/mmr.2019.10513
Pages: 2583-2590
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Annexin A3 (ANXA3) is highly expressed in different types of cancers, but the impact of ANXA3 in bone tumors is still not clear. In the present study, the expression of ANXA3 in osteosarcoma cells was first confirmed by cellular immunofluorescence. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis were used to detect the expression of ANXA3 in osteoblasts in the osteosarcoma cell lines U2OS and HOS. Furthermore, small interfering (si)‑RNA were transfected into U2OS and HOS cells via a liposome‑mediated method. Then once ANXA3 had been successfully downregulated in U2OS and HOS cells, the cells were collected and total protein was extracted after 48 h of transfection. Western blot analysis was used to confirm successful ANXA3 transfection into osteosarcoma cells and the apoptotic rate of HOS and U2OS was detected by flow cytometry. The expression of ANXA3 in the osteosarcoma cell lines HOS and U2OS were first observed by confocal laser scanning microscopy, and was then detected by RT‑qPCR and western blotting. The mRNA and protein levels of ANXA3 in the osteosarcoma cell lines HOS and U2OS were significantly increased compared with osteoblasts, particularly in HOS cells. When siRNA was transfected into HOS and U2OS cells, the protein expression level of ANXA3 was measured via western blotting. The results indicated that the expression of ANXA3 was significantly decreased. In addition, to determine whether ANXA3 knockdown induced cell apoptosis, the present study analyzed the apoptotic rate by flow cytometry. The results revealed that ANXA3 knockdown markedly increased HOS and U2OS cell apoptosis. To the best of our knowledge, the present study is the first to confirm that ANXA3 is highly expressed in the osteosarcoma cell lines HOS and U2OS. In addition, downregulation of ANXA3 expression in HOS and U2OS cells could increase apoptotic ability.

View Figures

View References

1	Michaelis J: Osteosarcoma. Lancet. 1:11741988. View Article : Google Scholar : PubMed/NCBI
2	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translation biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
3	Gianferante DM, Mirabello L and Savage SA: Germline and somatic genetics of osteosarcoma-connecting aetiology, biology and therapy. Nat Rev Endocrinol. 13:480–491. 2017. View Article : Google Scholar : PubMed/NCBI
4	Li ZX, Wang RY and Tang JC: Sodium valproate enhance γδ T cells killing osteosarcoma. Chin J Exp Surg. 33:154–157. 2016.
5	Perron B, Lewit-Bentley A, Geny B and Russo-Marie F: Can enzymatic activity, or otherwise, be inferred from structural studies of annexin III? J Biol Chem. 272:11321–11326. 1997. View Article : Google Scholar : PubMed/NCBI
6	Gerke V, Creutz CE and Moss SE: Annexins: Linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 6:449–461. 2005. View Article : Google Scholar : PubMed/NCBI
7	Moss SE and Morgan RO: The annexins. Genome Biol. 5:2192004. View Article : Google Scholar : PubMed/NCBI
8	Gerke V and Moss SE: Annexins: From structure to function. Physiol Rev. 82:331–371. 2002. View Article : Google Scholar : PubMed/NCBI
9	Hamelin-Peyron C, Vlaeminck-Guillem V, Haidous H, Schwall GP, Poznanovic S, Gorius-Gallet E, Michles S, Larue A, Guillotte M, Ruffion A, et al: Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variablility. Clin Biochem. 47:901–908. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wu N, Liu S, Guo C, Hou Z and Sun MZ: The role of annexin A3 playing in cancers. Clin Transl Oncol. 15:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zeidan B, Jackson TR, Larkin SE, Cutress RI, Coulton GR, Ashton-Key M, Murray N, Packham G, Gorgoulis V, Garbis SD and Townsend PA: Annexin A3 is a mammary marker and potential neoplastic breast cell therapeutic target. Oncotarget. 6:21421–21427. 2015. View Article : Google Scholar : PubMed/NCBI
12	Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, et al: ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Reports. 5:45–59. 2015. View Article : Google Scholar : PubMed/NCBI
13	Liu YF, Xiao ZQ, Li MX, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX and Chen ZC: Quantitative promote analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 217:54–64. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu YF, Chen YH, Li MY, Zhang PF, Li GQ, Xiao ZQ and Chen ZC: Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma. Med Oncol. 29:174–184. 2012. View Article : Google Scholar : PubMed/NCBI
15	Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX and Xia JC: Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 54:598–607. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yan X, Yin J, Yao H, Mao N, Yang Y and Pan L: Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 70:1616–1624. 2010. View Article : Google Scholar : PubMed/NCBI
17	Tong SW, Yang YX, Hu HD, An X, Ye F, Hu P, Ren H, Li SL and Zhang DZ: Proteomic investigation of 5-flourouracil resistance in a human hepatocellular carcinoma cell line. J cell Biochem. 113:1671–1680. 2012.PubMed/NCBI
18	Pénzváltó Z, Tegze B, Szász AM, Sztupinszki Z, Likó I, Szendrői A, Schäfer R and Győrffy B: Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One. 8:e595032013. View Article : Google Scholar : PubMed/NCBI
19	Li ZX: Potential of human γδ T cells for immunotherapy of osteosarcoma. Mol Biol Rep. 40:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Mussunoor S and Murray GI: The role of annexins in tumor development and progression. J Pathol. 216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
22	Shao P, Qu WK, Wang CY, Tian Y, Ye ML, Sun DG, Sui JD, Wang LM, Fan R and Gao ZM: MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway. Am J Transl Res. 9:4300–4307. 2017.PubMed/NCBI
23	Yang YM, Kim SY and Seki E: Inflammation and liver cancer: Molecular mechanisms and therapeutic targets. Semin Liver Dis. 39:26–42. 2019. View Article : Google Scholar : PubMed/NCBI
24	Li Z, Zhang L, Gao M, Han M, Liu K, Zhang Z, Gong Z, Xing L, Shi X, Lu K and Gao H: Endoplasmic reticulum stress triggers xanthoangelol-induced protective autophagy via activation of JNK/c-Jun Axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 38:82019. View Article : Google Scholar : PubMed/NCBI
25	Kim JB, Lee S, Kim HR, Park SY, Lee M, Yoon JH and Kim YJ: Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro. Oncol Lett. 15:8723–8728. 2018.PubMed/NCBI
26	Jin Y, Mao J, Wang H, Hou Z, Ma W, Zhang J, Wang B, Huang Y, Zang S, Tang J and Li L: Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo. Biomed Pharmacother. 67:337–345. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T and Sakurai T: Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer. 106:1997–2003. 2012. View Article : Google Scholar : PubMed/NCBI
28	Pan Q, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, et al: Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Stem Cells. 33:354–366. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhou T, Li Y, Yang L, Yang L, Tang T, Zhang L and Shi J: Annexin A3 as a prognostic biomarker for breast cancer: A retrospective study. Biomed Res Int. 2017:26036852017. View Article : Google Scholar : PubMed/NCBI
30	Zeng C, Ke Z, Song Y, Yao Y, Hu X, Zhang M, Li H and Yin J: Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance. Exp Mol Pathol. 95:23–31. 2013. View Article : Google Scholar : PubMed/NCBI
31	Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX and Chen ZC: Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 217:54–64. 2009. View Article : Google Scholar : PubMed/NCBI
32	Li J, Zhou T, Liu L, Ju YC, Chen YT, Tan ZR and Wang J: The regulatory role of Annexin 3 in nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma. Pathol Res Pract. 214:1719–1725. 2018. View Article : Google Scholar : PubMed/NCBI
33	Jeun M, Park S, Kim Y, Choi J, Song SH, Jeong IG, Kim CS and Lee KH: Self-Normalized detection of ANXA3 from untreated urine of prostate cancer patients without digital rectal examination. Adv Healthc Mater. 62017.
34	Liu YF, Liu QQ, Zhang YH and Qiu JH: Annexin A3 knockdown suppresses lung adenocarcinoma. Anal Cell Pathol (Amst). 2016:41314032016.PubMed/NCBI
35	Zhou T, Li Y, Yang L, Liu L, Ju Y and Li C: Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol Rep. 37:388–398. 2017. View Article : Google Scholar : PubMed/NCBI
36	Li ZX, Wang RY and Tang JC: Type I IFN-mediated enhancement of anti-osteosarcoma cytotoxicity of human γδ T cells. Chin J Immun. 11:1533–1535, 1542. 2014.
37	Li Z, Zhang J, Tang J and Wang R: Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors. Oncotarget. 7:84388–84397. 2016.PubMed/NCBI
38	Li Z, Xu Q, Peng H, Cheng R, Sun Z and Ye Z: IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. Int Immunopharmacol. 11:496–503. 2011. View Article : Google Scholar : PubMed/NCBI
39	Li Z, Peng H, Xu Q and Ye Z: Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 30:824–830. 2012. View Article : Google Scholar : PubMed/NCBI
40	Li ZX, Zhang JZ, Wang ST, Wang RY and Tang JC: Celastrol increases osteosarcoma cells line HOS lysis by γδ T cells through TRAIL way. Chin J Immun. 32:1777–1780. 2016.